Skip to main content
Equibles
TSHA logo

TSHA · Taysha Gene Therapies, Inc.

Track TSHA — free

Use TSHA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about TSHA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.09 -0.02 (-0.33%) At close · Aug 21
Market Cap
$1.98B
Shares
325.83M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.09 Open$6.18 Day$6.02–6.24 52W close$2.83–6.98 Avg vol 30d2.9M Short int46.7M · 14.3% float · 19.0d Short vol59% Last earningsAug 11, 2026 DataSep 2020–Aug 2026 Filing10-Q · Aug 11

Up next

Next earnings call
Nov 10, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 15.1 · calm Equity put/call 0.51
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg +14%
      above
      Price vs 50-day avg −1%
      below
      RSI (14) 49
      neutral
      MACD trend Negative
      52-week position 79%
      mid-range
      Momentum
      relative strength
      Very Strong
      1-month return +10%
      trailing
      6-month return +34%
      trailing
      YTD return +11%
      this year
      Relative strength +23%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $6 › 200d $5 — 50d above 200d
      Institutional flow Accumulating
      +8% holders QoQ · +41 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      14.33% of float · ▲ +3.1% MoM · 19.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      208 holders — near 3-yr high, broad support
      Squeeze score 79
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +17%
      Y/Y
      EPS growth +6%
      Y/Y
      Free cash flow $-93.8M
      Balance sheet $269.7M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 91%
      annualized · 1-yr
      Max drawdown −31%
      past year
      ATR 6.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +14% Bullish
      Price vs 50-day avg
      −1% Neutral
      RSI (14)
      49 Neutral
      MACD trend
      Negative Bearish
      52-week position
      79% Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $6 › 200d $5 — 50d above 200d
      Institutional flow Accumulating
      +8% holders QoQ · +41 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      14.33% of float · ▲ +3.1% MoM · 19.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      208 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $3 Now $6 · 79% Range high $7
      vs 200-day avg +14% vs 50-day avg -1%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      patients dosed in REVEAL pivotal trial 17 Q2 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      TSHA
      Taysha Gene Therapies, Inc.
      this stock
      		$1.98B +10.7% +17.3% — 14.3%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $138.91B +20.9% +46.2% 31.9 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $85.87B +8.1% +20.8% 20.7 3.3%
      ARGX
      Argenx SE
      		 $64.66B +23.6% — — 2.1%
      CSLLY
      Csl Ltd
      		 $58.31B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      208
      % held
      92.2%
      Net QoQ
      +34.3M sh
      Top holder
      Avoro Capital Advisors LLC
      Held Float
      View
      Held by Funds
      Fund positions
      159
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      46.7M
      Days to cover
      19.0d
      Change
      +1.4M sh
      View
      Short Volume
      Short vol %
      59%
      As of
      Aug 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      1.9K
      Value
      $11.1K
      As of
      Jul 20, 2026
      View
      Off-Exchange
      Off-exchange %
      46.6%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $9.8M
      Net income (FY)
      $-109.0M
      EPS diluted
      $-0.34
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 11, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $1.3M
      Shares
      200.0K
      Filed
      Jul 10, 2026
      View
      Exempt Offerings
      Offering
      $150.0M
      Filed
      Aug 25, 2023
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 11, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      TSHA +2.4% +10.3% +34.4% +3.9% +10.7%
      SPY -1.4% +3.6% +11.6% +2.5% +12.3%
      vs SPY +3.7% +6.7% +22.9% +1.4% -1.6%
      Key facts CIK 1806310 CUSIP 877619106 13F (30d) 198 filings 194 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)